Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.
MWN-AI** Summary
Onconetix, Inc., a biotechnology firm specializing in men's health and oncology, announced a significant financing achievement amounting to $12.9 million through a private placement of Series D Convertible Preferred Stock and associated warrants. This deal, finalized on September 22, 2025, involved the issuance of shares convertible to common stock and warrants exercisable for future equity at a price of $3.6896 per share. Approximately $9.3 million of the proceeds was allocated in cash, while the remainder addressed outstanding debts to investors.
In addition to the financing news, Onconetix also disclosed the termination of its merger agreement with Ocuvex, Inc., which further emphasized its strategic shift. The company used about $6.3 million of the financing proceeds to settle an $8.8 million debt with Veru, Inc. The remaining $2.5 million of this debt was settled by converting it into Series D Preferred Stock and warrants, aligning the financing with ongoing operational needs.
The company indicated that the net cash proceeds would be directed to cover costs stemming from the merger's termination and for general corporate expenditure. Onconetix operates in a challenging biotech landscape but holds potential with its acquisition of Proteomedix and its prostate cancer diagnostic product, Proclarix, which is approved in the European Union.
Onconetix filed a Current Report with the SEC to provide detailed insights into this financing arrangement while also indicating a need for shareholder approval regarding the issuance of stocks tied to the new financing. The company remains cautiously optimistic about future growth despite inherent market risks. Investors are encouraged to consider risk factors outlined in Onconetix’s latest Annual Report as they assess the company’s outlook.
MWN-AI** Analysis
Onconetix, Inc. (Nasdaq: ONCO) recently announced a $12.9 million private placement of Series D Preferred Stock and Warrants, alongside the termination of a merger agreement with Ocuvex, Inc. and the settlement of an $8.8 million debt with Veru, Inc. This series of significant financial maneuvers presents both risks and opportunities for investors.
The financing transaction, which includes cash proceeds used to address debt, signals a strategic move towards enhanced liquidity while settling obligations that could have weighed down the company's financial standing. The issuance of Series D Preferred Stock and the accompanying Warrants could dilute existing shareholders if converted into common stock, thus it's crucial for potential investors to closely monitor stockholder voting outcomes regarding this issuance.
Onconetix’s decision to terminate the merger with Ocuvex may imply a strategic pivot. While mergers can provide synergistic benefits, the abandonment of this agreement suggests Onconetix is perhaps seeking to preserve capital or recalibrate its growth strategy. Investors should evaluate how this shift impacts the company’s long-term business model and market positioning, particularly in men’s health and oncology.
The company’s reliance on proceeds for general corporate purposes highlights a critical need for future capital to effectively commercialize its diagnostic product, Proclarix. Given the inherent risks in the biotech sector, particularly concerning regulatory approvals and commercialization hurdles, investors should approach with caution.
In conclusion, while Onconetix’s recent activities might enhance its short-term liquidity and relieve some financial burdens, the risks associated with dilution and the uncertain path forward warrant a nuanced view. Investors should assess their risk tolerance and consider the long-term potential of Onconetix in the evolving biotech landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CINCINNATI, OH, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the “Company”) a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men’s health and oncology, announced the September 22, 2025 signing and closing of a private placement of (i) shares of the Company's Series D Convertible Preferred Stock, $0.00001 par value (the "Series D Preferred Stock"), and (ii) warrants (the "Warrants") to purchase up to an aggregate of 4,362,827 shares of the Company's common stock, $0.00001 par value per share (the "Common Stock"), for an aggregate purchase price of approximately $12.9 million (the “Financing Transaction”). Approximately $9.3 million was paid in cash and the balance was used to offset certain amounts owed by the Company to certain investors. The Series D Preferred Stock are initially convertible into an aggregate of 4,362,827 shares of Common Stock, subject to certain anti-dilution adjustments. The Warrants will have an initial exercise price of $3.6896 per share, subject to certain anti-dilution adjustments, and are exercisable beginning on the issuance date (the "Initial Exercisability Date") and expiring on the third anniversary of the Initial Exercisability Date.
The Company has filed a Current Report on Form 8-K with the Securities and Exchange Commission on September 26, 2025, with additional details of the transaction. The Company agreed to seek stockholder approval for the issuance of all of the shares of Common Stock issuable upon conversion of the Series D Preferred Stock and exercise of the Warrants in accordance with the rules and regulations of the Nasdaq Stock Market.
In full satisfaction of the Company’s approximately $8.8 million debt to Veru, Inc., approximately $6.3 million of the cash proceeds from the Financing Transaction was paid to Veru, Inc., and the remaining $2.5 million of debt was converted into 3,125 shares of Series D Preferred Stock and 846,975 warrants as part of the Financing Transaction. The Company intends to use the remaining net cash proceeds from the Financing Transaction to cover costs and expenses associated with the termination of a previously contemplated business combination with Ocuvex, Inc., and for working capital and general corporate purposes.
About Onconetix, Inc.
Onconetix (Nasdaq: ONCO) is a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men’s health and oncology. Through our acquisition of Proteomedix, we own Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union (“EU”) under the IVDR. For more information, visit www.onconetix.com .
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements (including, without limitation, the use of proceeds from the Financing Transaction as described herein) are based on Onconetix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, market and other conditions; risks related to Onconetix’s ability to commercialize or monetize Proclarix and integrate the assets and commercial operations acquired in the share exchange with Proteomedix; risks related to the Company’s present need for capital to commercially launch Proclarix and have adequate working capital; and risks related to Onconetix’s ability to raise additional capital to sustain the Company’s operations. As with any commercial-stage pharmaceutical product or any product candidate under clinical development, there are significant risks in the development, regulatory approval and commercialization of biotechnology products. Onconetix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Onconetix’s Annual Report on Form 10-K, filed with the SEC on June 2, 2025 and periodic reports filed with the SEC on or after the date thereof. All of Onconetix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Contact Information:
Onconetix, Inc.
201 E. Fifth Street, Suite 1900
Cincinnati, OH 45202
Phone: (513) 620-4101
Investor Contact Information:
Onconetix Investor Relations Email: investors@onconetix.com
FAQ**
How does Onconetix Inc. (ONCO) plan to utilize the remaining net cash proceeds from the recent financing to support its objectives in men’s health and oncology?
What are the expected impacts of the private placement of shares and warrants on Onconetix Inc. (ONCO)'s share structure and market strategy?
Given the risks associated with commercialization and regulatory approval, what contingency plans does Onconetix Inc. (ONCO) have to ensure sustainable operations moving forward?
How does Onconetix Inc. (ONCO) evaluate the success of Proclarix® in the market, and what milestones are they aiming to achieve post-launch in the European Union?
**MWN-AI FAQ is based on asking OpenAI questions about Onconetix Inc. (NASDAQ: ONCO).
NASDAQ: ONCO
ONCO Trading
-17.21% G/L:
$0.507 Last:
169,364 Volume:
$0.569 Open:
